| Name | Title | Contact Details |
|---|---|---|
Miranda Kroehl |
Associate Vice President, Business Insights & Analytics Data Science | Profile |
Xuan Li |
Chief Operating Officer, Lilly Biotechnology Discovery Research | Profile |
Jodi Leeper |
Sr. Director - Technology Organizational Change Management Lead | Profile |
Yana Collins |
Sr. Director Global Quality Transformation & Technology | Profile |
Brigid Hayes |
Associate Director - IT Systems Program Manager | Profile |
BioScrip is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ocusoft is a Rosenberg, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trefoil is a biotechnology company focused on leveraging its engineered fibroblast growth factor-1 protein (eFGF-1) technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which are debilitating and cause a significant amount of preventable blindness throughout the world.
Secant Pharma is a Feasterville Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.